We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Second financing in a month brings in another $11.28mm for Xoma
16 Jun 2009
Executive Summary
Just weeks after netting $9.4mm, Xoma has closed on another private sale of shares. This time it netted $11.28mm through the registered direct offering of 10.4mm units to certain institutional investors at $1.15 each (a 40% premium). The units consist of one common share and a five-and-a-half-year warrant to buy half of a share (up to 5.2mm shares at $1.30 apiece). The proceeds will be used to continue developing XOMA052, an anti-IL-1 beta antibody. Canaccord Adams and Wedbush PacGrow Life Sciences were the placement agents.
Deal Industry
Pharmaceuticals
Biotechnology
Drug Discovery Tools
Synthesis Technologies, Production Processes
Large Molecule
Antibodies
Deal Status
Final
Deal Type
Financing
Private Investment in Public Equity
Private Placement
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?